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Abstract
Objective: To evaluate the influence of Everolimus (RAD001) on chemically induced urothelial lesions in mice and its influence on in
vitro human bladder cancer cell lines.
Methods: ICR male mice were given N-butyl-N-(4-hydroxybutyl) nitrosamine in drinking water for a period of 12 weeks. Subsequently,
RAD001 was administered via oral gavage, for 6 weeks. At the end of the experiment, all the animals were sacrificed and tumor development
was determined by means of histopathologic evaluation; mammalian target of rapamycin (mTOR) expressivity was evaluated by
immunohistochemistry. Three human bladder cancer cell lines (T24, HT1376, and 5637) were treated using a range of RAD001
concentrations. MTT assay, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and flow cytometry were used to
assess cell proliferation, apoptosis index, and cell cycle analysis, respectively. Immunoblotting analysis of 3 cell line extracts using mTOR
and Akt antibodies was performed in order to study the expression of Akt and mTOR proteins and their phosphorylated forms.
Results: The incidence of urothelial lesions in animals treated with RAD001 was similar to those animals not treated. RAD001 did not
block T24 and HT1376 cell proliferation or induce apoptosis. A reduction in cell proliferation rate and therefore G0/G1 phase arrest, as well
s a statistically significant induction of apoptosis (P  0.001), was only observed in the 5637 cell line.
Conclusion: RAD001 seems not to have a significant effect on chemically induced murine bladder tumors. The effect of RAD001 on
umor proliferation and apoptosis was achieved only in superficial derived bladder cancer cell line, no effect was observed in invasive cell
ines. © 2011 Elsevier Inc. All rights reserved.
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Cancer is a major public health problem worldwide.
Bladder cancer is the second most common tumor of the
urinary tract [1,2] and its incidence over the last half century
as increased. Urothelial tumors of the bladder are usually
uperficial at presentation in 70% to 80% of patients, and
nvasive in 20% to 30% [3]. The invasive and metastatic
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2 C. Vasconcelos-Nóbrega et al. / Urologic Oncology: Seminars and Original Investigations xx (2011) xxxbladder cancers represents the leading cause of morbidity
and mortality among bladder cancer patients because the
therapeutic protocols currently available fail to provide an
effective response or to provide positive outcomes. New
strategies and new therapeutic agents should therefore be
tested.
Animal models of bladder cancer have been widely used
in the preclinical development of new and more effective
therapeutic agents, as well as to enable a deeper and more
accurate understanding of the process of bladder carcino-
genesis [4,5]. Oral administration over a period of 12
weeks [6] of N-butyl-N-(4-hydroxybutyl) nitrosamine
(BBN) induces the development of invasive urothelial
cancers that exhibit similar morphological characteristics
and molecular events, such as their DNA content, prolif-
erative index, and p53 overexpression, as human urothe-
lial bladder cancer [7].
Activation of the PI3K/Akt/mTOR axis was associated
with early events in carcinogenesis and the interruption of
pathways, which led to antiproliferation, antisurvival, anti-
angiogenic, and proapoptotic effects [8].
RAD001 (everolimus) is an oral mTOR inhibitor with
n antineoplastic activity similar to rapamycin (siroli-
us), an anticancer agent used on solid tumors [9 –13].
AD001 has a potent antiproliferative effect when used
gainst human breast cancer cell lines, lymphoma cells,
rostate cancer cells, and gastric cancer [14]. Its thera-
eutic effects are under clinical evaluation for use on
ifferent types of solid cancer, including renal cell and
ndometrial cancer [15]. It has a shorter half-life and
reater bioavailability than rapamycin and after entering
ells it binds with FKBP-12, an immunophilin. This
orms a complex that binds to the mammalian target of
apamycin (TOR), thus inhibiting growth factor induced
ransduction signals that mediate cellular division, retard-
ng, or arresting the cell cycle in G1 phase or, in some
ases, inducing apoptosis [12,14,16 –19].
In this study, we evaluated the therapeutic effects of
AD001 on mice with BBN induced neoplastic urothelial
esions similar to those found in humans, as well as its effect
n vitro on 3 human bladder cancer cell lines (T24, HT1376,
Fig. 1. Experimental design (arrows represend 5637).. Materials and methods
.1. Chemicals
BBN was purchased from Tokyo Kasei Kogyo Co. Ltd.
Tokyo, Japan), RAD001 (Certican) was purchased from
ovartis (Basel, Switzerland) (for in vivo study) and from
igma (St. Louis, MO) (for in vitro study).
.2. In vivo studies
.2.1. Animals
Four week old male ICR mice were obtained from Har-
an Interfauna Inc. and housed in plastic cages with wood
hips for bedding. All mice used in the experiment were
cclimatized for 1 week under routine laboratory conditions
efore starting the experiments. They were placed in a
emperature (23  2°C) and humidity (50%  10%) con-
trolled environment in which a 12:12 hour light:dark cycle
was maintained. All animals had free access to water and a
standard lab diet, and all procedures were performed in
accordance with the European Communities Council Direc-
tive 86/609/ECC.
2.2.2. Animal experiments
After 1 week of quarantine, a total of 51 ICR mice were
randomly divided into 4 groups (Fig. 1) (group I: n  10;
group II: n  12; group III: n  15; group IV: n  14),
groups II, III, and IV received BBN (0.05%) in drinking
water for 12 weeks. Group I was used as a negative control
group, drinking only tap water. One week after bringing
BBN exposure to an end, groups I and II were euthanized by
means of pentobarbital overdose anesthesia to evaluate the
presence of any preneoplastic and neoplasic lesions induced
by BBN. After being treated with BBN solution for 12
weeks, groups III and IV were maintained with normal tap
water during 1 additional week. Group III was treated with
RAD001, 2 days a week (5 mg/kg) [20] by oral gavage for
6 consecutive weeks, until the 19th week of the experiment,
with group IV being used as the treatment control group.
For the duration of the study, the mice’s state of health
was monitored daily. The animals’ drinking solution was
period after which euthanasia took place).changed once a week or earlier if necessary, and the volume
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3C. Vasconcelos-Nóbrega et al. / Urologic Oncology: Seminars and Original Investigations xx (2011) xxxdrunk was recorded. Weekly food intake was also noted.
Their body weights were initially measured once a week
and then twice a week after treatment had begun, allowing
us to adjust RAD001 doses to individual weight variations.
2.2.3. Evaluation of treatment
All surviving animals from groups III and IV were eu-
thanized, according to the technique described above, 1
week after ending RAD001 treatment. Necropsies were
carried out and urinary bladders of the mice were collected
according to the technique described by Oliveira et al.
(2009) [6]. After overnight fixation, bladders were cut lon-
itudinally and their mucosal surface was carefully exam-
ned for the existence of macroscopic lesions. After this
rocedure, they were embedded in paraffin and 2 m sec-
ions were cut and stained with hematoxylin and eosin. All
ther organs were also examined macroscopically for any
hanges, and their weights were recorded.
.3. Histology
Histologic slides were observed under a light microscope
y 2 investigators. All slides were examined without prior
nowledge of the treatment given to the animals whose
issue samples were under investigation. Histologic lesions
ound in different groups were classified and staged accord-
ng to World Health Organization guidelines [21]. Urothe-
ial lesions were categorized as simple hyperplasia, nodular
yperplasia, dysplasia, carcinoma in situ, papilloma, low
rade non invasive papillary urothelial carcinoma, high
rade non invasive papillary urothelial carcinoma, invasive
rothelial carcinoma, and squamous metaplasia.
.4. Immunohistochemistry
The mTOR (7C10) rabbit mAb (#2983; Cell Signaling
echnology, Danvers, MA) was used as the primary anti-
ody. The immunohistochemistry assay was performed
ith an autostainer (LVI; Labvision Corporation, Cheshire,
K) using the Ultra VisionHP-125-HL detection kit (Lab-
ision Corporation). The staining procedure using this kit is
ased on the labeled streptavidin biotin method. Heat anti-
en retrieval was performed by slides pretreatment in a jar
ith sodium citrate buffer pH 6 and heated 3 times for 5
inutes in a microwave oven at 700 W. Slides were incu-
ated 60 minutes at 37°C with the primary antibody (1:50).
araffin sections from human lung carcinoma were used as
positive control.
.5. Immunohistochemical evaluation
Sections were examined under light microscopy. The
mmunohistochemical expression was classified as exhibit-
ng positive staining if the pattern of immunoreactivity was
dentical to that of the cytoplasm staining of normal urothe-ial cells for mTOR activity. Negative staining was consid-
red if lesions/tumors showed no immunoreactivity.
.6. In vitro studies
.6.1. Tumor cell lines and culture conditions
In vitro study was performed using 2 established human
nvasive bladder cancer cell lines: T24 and HT1376, and 1
uperficial urothelial bladder cancer cell line: 5637 (the first
ine was provided by DSMZ, Düsseldorf, Germany and the
ast 2 lines provided by Dr. Paula Videira of the Universi-
ade Nova de Lisboa). All the cell lines were cultured as a
onolayer in RPMI 1640 culture medium (PAA, Pasching,
ustria) supplemented with 10% heat inactivated fetal calf
erum (Biological Industries, Kibbutz Beit Haemek, Israel),
00 U/mL penicillin (Biological Industries), 100 g/mL
streptomycin (Biological Industries) and 2 mM L-Glu-
tamine (Sigma Aldrich, St. Louis, MO). Cells were main-
tained at 37°C in a humidified atmosphere with 5% CO2–
5% O2 and were routinely subcultured by trypsination. All
experiments were performed during exponential cell
growth. All bladder cancer cell lines expressed higher
amounts of VEGF-A, however, the 5637 cell line had the
highest VEGF-A expression of any cell line studied [22].
.6.2. Drug exposure
Bladder cancer cell lines were exposed to concentrations
f RAD001 ranging from 0 to 2 M (0; 0.05; 0.1; 1; 2 M)
over the course of 72 hours to assess dose response profiles.
An untreated control group was processed in the same way
as the treatment samples but in a drug free medium, and
the evaluation of the cytotoxicity effect was performed
immediately after the end of drug exposure. The concen-
tration of RAD001 represented the average IC30 dose at
2 hours from each respective single concentration. IC30
is defined as the drug concentration that causes a 30%
reduction in cell numbers compared with that of the
untreated control (IC30  30% growth inhibition) [23].
.6.3. Cell viability assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tet-
azolium bromide; Sigma Aldrich) assay was used to assess
he relative percentage of metabolically active cells relative
o untreated controls [24]. In brief, trypsinized tumor cells
were resuspended in a medium at 2–3 104 cells/ml, based
on the growth characteristics of each cell line after verifying
cell viability via trypan blue dye exclusion. One hundred l
f cell suspension were seeded into each well of a 96 well
at bottom microtiter (Sarstedt, Newton, NC) and plates
ere incubated for 24 hours to allow adherent cell growth.
fter overnight incubation, the medium was removed and
00 L of the different reagent solutions in complete me-
dium and medium control were distributed in each well and
incubated for 72 hours. After incubation, 10 L of MTT dye
working solution (5 mg/ml) was added to each well. After 4
hours of incubation, the supernatant in the wells was re-
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4 C. Vasconcelos-Nóbrega et al. / Urologic Oncology: Seminars and Original Investigations xx (2011) xxxmoved and replaced by 100 l/well of dimethylsulfoxide
DMSO, Sigma Aldrich). The absorbance (A) values of
ach well were recorded at 492 nm on an automatic ELISA
late reader (Multiskan EX; Labsystems). The medium con-
aining tetrazolium dye but without cells (blank), was used
s a negative control. After the blank correction, the relative
iability was calculated as follows: Aexp group/Acontrol  100
20,25]. In each experiment, triplicate wells were performed
or each RAD001 concentration and the assay was repeated
n 2 independent experiment replications.
.6.4. TUNEL assay
In order to detect and quantify DNA strand breaks in
poptotic bladder cells, terminal deoxynucleotidyl trans-
erase dUTP nick end labeling (TUNEL) assay was per-
ormed. Cells (2  104) were then seeded and allowed to
ttach overnight. Subsequently, cells were treated with
AD001 (2 M) and incubated for 72 hours. After treat-
ent, cells were trypsinized, washed with PBS, and fixed
ith 4% paraformaldehyde for 1 hour at 15 to 25°C. The in
itu cell death detection kit fluorescein (Roche, IN) was
dapted from the manufacturer’s instructions. Slides were
bserved using a fluorescence microscope (Nikon Eclipse
400, Tokyo, Japan). Cells were defined as apoptotic if the
uclear area of cells was labeled positively (green color).
he number of cells undergoing apoptosis was counted in
Table 1
Mean and relative weight of bladder, kidney, and liver (value  SD)
Group Mean weight (g)
Bladder Right kidney Left kidney Liver
I 0.280  0.113 0.327  0.018 0.341  0.042 2.32  0.41
I 0.269  0.115 0.347  0.041 0.343  0.051 1.95  0.28
II 0.167  0.05a 0.328  0.091 0.292  0.0107b 2.30  0.46
IV 0.38  0.28 0.376  0.059 0.407  0.165 2.08  0.25
SD  standard deviation.
a Different from group IV (P  0.01). b Different from group IV (P 
0.0139). e Different from group IV (P  0.017). f Different from group II
P  0.033).
able 2
ncidence of urothelial lesions in ICR mice exposed to N-butyl-N-(4-hydr
Histologic lesion Group I H2O
(n  10)
Grou
(n 
ormal urothelium 10 (100%) 0 (0
imple hyperplasia 0 (0%) 8 (6
odular hyperplasia 0 (0%) 7 (5
ysplasia 0 (0%) 12 (1
arcinoma in situ 0 (0%) 4 (3
apilloma 0 (0%) 0 (0
ow-grade noninvasive papillary
urothelial carcinoma
0 (0%) 0 (0
igh-grade noninvasive papillary
urothelial carcinoma
0 (0%) 0 (0
nvasive urothelial carcinoma 0 (0%) 4 (3
quamous metaplasia 0 (0%) 8 (67%)andom fields on each slide. At least 200 cells were counted
magnification 1000) in random fields on each slide. The
poptotic index (AI) was determined as follows: AI (%) 
number of apoptotic cells/total number of cells)  100
26].
.6.5. Cell cycle analysis
Cells (1  106) were plated in 6 well plates and incubated
for 24 hours. Then RAD001 was added in serial dilutions.
After 72 hours of incubation, cells were trypsinized, washed
with PBS, and fixed in ice cold ethanol 70% for at least 1
hour. Propidium iodide (PI, Cycloscope DNA Cytometry,
Cytognos, Maia, Portugal) was added in order to label total
cellular DNA, and cell cycle analysis was carried out using
a Coulter EPICS XL-MCL flow cytometer. DNA-content
histograms were analyzed with Modfit LT 3.0 software
(Verity) to determine the percentage of cells in each cell
cycle: G0/G1, S and G2/M. Cells with DNA content less than
that of G0/G1-phase cells were considered to be apoptotic
(sub-G0/G1). Each independent experiment was performed
in triplicate.
2.7. mTOR and Akt expression analysis
Whole cell extracts were obtained from mechanical ho-
mogenization of cell pellets in 1% SDS containing phos-
elative weight (g)
ladder Right kidney Left kidney Liver
.063  0.0022 0.0075  0.00054f 0.0078  0.001g 0.053  0.0091
.069  0.003 0.009  0.001 0.0089  0.001 0.050  0.0051
.004  0.001e 0.008  0.002 0.0072  0.0026 0.0566  0.0110h
0094  0.0077 0.0089  0.001 0.0097  0.0042 0.0495  0.0047
c Different from group II (P  0.0024). d Different from group IV (P 
0.003). g Different from group II (P  0.045). h Different from group IV
l) nitrosamine and treated with RAD001
N Group III BBNRAD001
(n  14)
Group IV BBNH2O
(n  13)
0 (0%) 0 (0%)
9 (64.3%) 10 (76.9%)
8 (57.14%) 9 (69.23%)
12 (85.7%) 13 (100%)
1 (7.1%) 2 (15.38%)
1 (7.1%) 0 (0%)
3 (21.4%) 1 (7.69%)
0 (0%) 1 (7.69%)
6 (42.86%) 7 (53.84%)R
B
c 0
0
d 0
1 0.
0.041).
(P oxybuty
p II BB
12)
%)
7%)
8.3%)
00%)
3%)
%)
%)
%)
3%)
9 (64.3%) 10 (76.9%)
nN
T
m
1
p
P
A
T
o
I
n
P
t
B
u
w
l
2
s
d
m
A
m
e
A
t
d
d
f
t
d
c
G
G
5C. Vasconcelos-Nóbrega et al. / Urologic Oncology: Seminars and Original Investigations xx (2011) xxxphatase inhibitors (P0044 and P5726, Sigma). Protein con-
centration was assayed by the colorimetric method “RC DC
protein assay” (Bio-Rad, Foster City, CA) using bovine
serum albumin (BSA) as standard. Samples from each cell
line, with no treatment and with 2 M RAD001, were then
diluted in Tris buffered saline (TBS; 100 mM Tris, 1.5 mM
NaCl, pH 8.0) to obtain a final protein concentration of 0.4
mg/mL and a volume of 100 l was slot-blotted into a
itrocellulose membrane (Whatman, Protan, Kent, UK).
onspecific binding was blocked with 5% (wt/vol) BSA in
BS-T (TBS with 0.5% Tween 20) for 1 hour, and the
embrane was then incubated with primary antibody (1:
000 dilution; rabbit anti-mTOR, #2983, rabbit anti-Phos-
ho-mTOR, #2971, rabbit anti-Akt, #9272, or rabbit anti-
hospho-Akt, #4058 from Cell Signaling, St. Louis, MO).
fter 1 hour incubation, the membrane was washed with
BS-T and incubated with anti-rabbit IgG peroxidase sec-
ndary antibody (1:1000; Amersham Pharmacia Biotech).
mmunoreactivity was detected with enhanced chemilumi-
escence reagents (ECL, Amersham Pharmacia Biotech,
iscataway, NJ) according to the manufacturer’s instruc-
ions, and images were recorded using X-ray films (Kodak
iomax Light Film, Sigma). Films were scanned in Molec-
lar Imager Gel Doc XR System (Bio-Rad) and analyzed
ith QuantityOne software ver. 4.6.3 (Bio-Rad). Protein
oading was controlled with Ponceau S staining.
.7.1. Statistical analysis
Statistical analysis was carried out using the SPSS 17.0
tatistical software (SPSS Inc., Chicago, IL). Body weight
ifferences and the mean and relative weights of the ani-
als’ livers, kidneys and bladders were assessed using
NOVA, with Bonferroni multiple comparison. Nonpara-
etric data were computed using the 2 test or Fisher’s
xact test with Bonferroni’s correction. For in vitro studies,
NOVA was performed, the equality of variances was
ested by Levene F test, and the statistical significance of
ifferences between the treatment and control groups were
etermined by Dunnett’s Multiple Comparison post-hoc test
or the MTT assay. The Pearson product-moment correla-
Table 3
Cytoplasm immunoreactivity of urothelial lesions with mTOR antibody in
RAD001
Group Histologic lesion
Group I (H2O) Normal urothelium (n 
Simple hyperplasia (n 
Nodular hyperplasia (n 
roup III (BBNRAD001) Dysplasia (n  12)
Invasive urothelial carci
Squamous metaplasia (n
Simple hyperplasia (n 
Nodular hyperplasia (n 
roup IV (BBNH2O) Dysplasia (n  8)
Invasive carcinoma (n 
Squamous metaplasia (n  6)ion coefficient was used to evaluate the correlation (linear
ependence) of the cell cycle, apoptosis, and RAD001 con-
entration. P values  0.05 were considered to be statisti-
cally significant.
3. Results
3.1. In vivo results
3.1.1. Animal growth and water and food consumption
The mean food and water intake was constant and similar
across the different groups throughout the whole study pe-
riod (data not shown).
Two mice one from each group III and IV died during the
experiment and therefore only surviving animals were con-
sidered for histopathologic examination. During the treat-
ment period, animals exhibited normal cage activity. Com-
paring the body weight of mice treated and those not treated
with RAD001, the differences were not statistically signif-
icant.
The mean weight of the animals’ livers, kidneys, and
bladders, as well as the relative organ weights (calculated as
the ratio of the mouse’s organ weight by the mouse’s
weight) are shown in Table 1.
3.2. Macroscopic and microscopic evaluation
Greyish-white urinary bladder masses which varied in
size were observed in groups II, III, and IV. The lesions
were invasive or less frequently pedunculated. The lesions
exhibited irregular surfaces and hemorrhage, while they
were distributed randomly throughout the entire urinary
bladder. No macroscopic urinary bladder changes were
identified in the control group (I). Stone formation in the
urinary bladder was not observed in any of the mice. No
macroscopic changes were seen in the liver, lung, kidneys,
and gastrointestinal tract of the animals involved.
ice exposed to N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with
Positive Negative
10 (100%) —
9 (100%) —
3 (60%) 2 (40%)
12 (100%) —
 5) 1 (20%) 4 (80%)
2 (33.3%) 4 (66.7%)
9 (100%) —
3 (100%) —
8 (100%) —
3 (75%) 1 (25%)ICR m
10)
9)
5)
noma (n
 6)
9)
3)
4)
5 (83.3%) 1 (16.7%)
c2
c
fi
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We conducted detailed histopathologic examination to
determine the degree of urothelial lesions induced by BBN.
These occurred only in the groups drinking BBN solution.
Animals from group I (control group) did not show any
histologic alterations, i.e., 100% of them exhibited a normal
urothelium. Table 2 summarizes the incidence of BBN-
induced urothelial lesions in each group.
3.4. Effects of RAD001 on urothelial tumorigenesis
The incidence of lesions between groups treated with
RAD001 and those not treated can be observed in Table 2.
Histologic alterations, such as simple and nodular hyperpla-
sia, dysplasia, and carcinoma in situ, exhibited a lower
incidence in animals treated with RAD001 (group III) than
animals not treated (group IV). There was a higher inci-
A
C
E
Fig. 2. (A) mTOR expression in normal mouse urothelium (400); (B) mT
(400); (D) mTOR expression in squamous metaplasia (400); (E) absen
invasive carcinoma (400). (Color version of figure is available online.)dence of papillomas and low-grade noninvasive papillary
urothelial carcinomas in animals treated with RAD001 com-
pared with animals not treated. The incidence of BBN-
induced invasive urothelial carcinoma was slightly lower in
mice treated with RAD001 (group III) and these differences
were not statistically significant.
3.5. Immunohistochemistry
mTOR immunoreactivity was performed in urinary blad-
ders samples from groups I, III, and IV. The results of the
mTOR immunoreactivity investigations are summarized in
Table 3 and discussed below using the diagnostic categories
reported on Table 2. In normal urothelium (Fig. 2A), the
ytoplasm was uniformly stained. Simple hyperplasia (Fig.
B) and dysplasia (Fig. 2C) showed a similar mTOR pattern
ompared with normal urothelium, with its expression con-
ned to urothelium cytoplasm. On squamous metaplasia
ression in simple hyperplasia (400); (C) mTOR expression in dysplasia
TOR expression in invasive carcinoma (400); (F) mTOR expression inB
D
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noreactivity pattern on basal layer, and loss of immunore-
activity in upper layers. mTOR immunohistochemical stain
performed on invasive carcinoma from animals treated with
RAD001 (Fig. 2E) revealed no staining in 80% of the
lesions observed. However, 75% of invasive carcinomas in
animals not treated revealed positive cytoplasm immunore-
activity (Fig. 2F).
3.6. In vitro results
3.6.1. Cytotoxic effect of RAD001 against bladder cancer
cell lines
RAD001 was added to the 3 bladder cancer cell lines and
its proliferation was quantified 72 hours after plating. The
cytotoxic activity of RAD001 is shown in Fig. 3. The IC
values were determined by MTT assay, according to expo-
sure time and dose of agent. RAD001 transiently inhibited
bladder cancer cell growth in a dose-dependent manner.
RAD001 is more effective on 5637 cells and exhibits an
IC30 at 1 M. Among the 3 cell lines tested, T24 cells
emonstrated significant resistance to RAD001 exposition,
s clearly documented by survival rates of 98.6%, 98.5%,
8.2%, and 94.5%, and were the least sensitive to RAD001,
ompared with HT1376 cell-line survival rates (99.2%,
2.3%, 92.4%, and 87.5%). Statistically, the anti-prolifera-
ive activity of RAD001 was only significant in the 5637
ell line, at all concentrations, compared with the control
roup (P  0.05).
Table 4
Apoptotic index values (%) in the three bladder-cancer cell lines after
exposure to RAD001
Groups T24 5637 HT1376
Control 1.5% 3% 1.5%
Fig. 3. Bladder cell lines (T24, HT1376 and 5637) were treated with differ
The data shown and bars represent the mean values  SD. *P  0.05 ven
RAD001 (2 M) 2.5% 6.5% 1.5%.7. TUNEL assay
To analyze RAD001 induced apoptosis in bladder-cancer
ells in vitro, TUNEL was carried out. Only an apoptotic
ndex value of 6.5% in 5637 cell line was observed as a
aximum apoptotic effect in this study. In T24 and HT1376
ell lines, this effect was minimal (Table 4).
.8. Cell cycle and apoptosis analysis
The comparative analysis of the percentage of cells in
ach cell cycle phase, spanning the control experiment and
he different drug concentrations tested, is summarized in
ig. 4. Cell cycle alterations were only observed in the 5637
ladder cancer cell line, namely a decrease in the percentage
f cells in S-phase fraction (P  0.029) between the control
nd treated cells. This effect on proliferative rate was in-
ersely correlated to drug concentration (r  0.978; P 
.004).
Regarding the relationship between drug treatment and
poptosis, no effects were observed in invasive bladder-
ancer cell lines T24 and HT1376 (Fig. 5). Only in the 5637
superficial cell line, a slight but statistically significant in-
crease in sub-G0/G1 fraction (P  0.001) was detected, an
effect which was positively correlated with concentrations
of RAD001 (r  0.956; P  0.011).
3.9. Effects of RAD001 on mTOR and Akt activation
To analyze RAD001 effect on mTOR activation, the
expression of mTOR and its phosphorylated form was
analyzed in all the cell lines. As can be depicted in Fig.
6, no significant expression differences of mTOR and on
its phosphorylation at Ser2448 were found due to RAD001
dministration in cell lines T24 and HT1376. In cell line
637, a significant decrease of mTOR expression was
es of RAD001 and cell proliferation was monitored using the MTT assay.
treated controls.ent dosoticed, though not paralleled by a significant increase in
nts. SD
d
8 C. Vasconcelos-Nóbrega et al. / Urologic Oncology: Seminars and Original Investigations xx (2011) xxxits phosphorylation. Once the major PI3K pathway led
from Akt to mTOR, the expression of Akt was also
evaluated by immunodetection of Akt and its phosphor-
ylated form. RAD001 treatment resulted in a slight in-
crease in the baseline expression of Akt in T24 and
HT1376 cell lines, and of its phosphorylation at Ser [473]
in HT1376 and 5637 cell lines.
4. Discussion
The mouse model of invasive bladder cancer induced by
BBN, as well as other animal models, plays an essential role
Fig. 4. Cell cycle analysis of the T24, 5637, and HT1376 bladder cancer c
cells in each cell cycle phases are mean  SD of 3 independent experime
Fig. 5. Sub-G0/G1 fraction on bladder-cancer cell lines T24, 5637, and
HT1376, after exposure to different concentration of RAD001. Sub-G0/G1
values are mean  SD of 3 independent experiments. For HT1376, the
values were zero for all the experimental conditions. SD  standard
eviation.in the evaluation of target cancer therapy. Disruption of the
mTOR pathway has been found in a number of human
tumors resulting in intracellular pro-survival and prolifera-
tive staining. In this study, we investigated the effect of the
mTOR inhibitor RAD001 on BBN induced bladder tumor-
igenesis in mice and human bladder cancer cells. This in-
vestigation took into account our previous studies concern-
ing the effects of sirolimus on the development of urothelial
lesions induced by BBN in mice and the in vitro effects on
the T24 cancer cell line [24,27]. For this purpose, male
ICR mice were exposed to BBN for 12 weeks and later
treated with RAD001 twice per week, for 6 consecutive
weeks. Three human bladder-cancer cell lines were
treated with various RAD001 concentrations during a
period of 72h.
According to our knowledge, this is the first report on the
influence of RAD001 on chemically-induced urothelial tu-
morigenesis in mice. The dosage used in our study seemed
to be well tolerated and no macroscopic changes were seen
in the liver, lungs, kidneys, and gastrointestinal tract of the
animals involved.
As determined by the observed results, the development
of BBN induced urothelial lesions in mice was not signifi-
cantly influenced by RAD001 treatments. Although there
were few mice in each group, the incidence of urothelial
preneoplastic lesions was slightly lower in those animals
treated with RAD001 compared with animals exposed to
BBN but not treated. The incidence of invasive lesions was
not affected by RAD001 treatments. The rate of low-grade
after exposure to different concentration of RAD001. The percentages of
 standard deviation.ell linesnoninvasive papillary urothelial carcinoma was higher in
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9C. Vasconcelos-Nóbrega et al. / Urologic Oncology: Seminars and Original Investigations xx (2011) xxxthe group treated with RAD001. In our previous study using
the same murine model (animals and time of exposition to
BBN), sirolimus was more effective, significantly reducing
the development of invasive lesions in comparison to non-
treated mice [6].
In the in vitro study, heterogeneous results were ob-
served. RAD001 had no effect on cellular proliferation and
apoptosis of T24 and HT1376 cell lines considering the
observed maintenance of Akt and mTOR expression and
the light increase of this phosphorylated forms. However,
a significant S-phase decrease and a concomitant arrest of
cells in G0/G1 cell cycle phase were seen in the 5637
ancer cell line, the only cell line studied in which a
ignificant decrease of mTOR expression was observed.
hese effects were correlated to drug concentration and
onsistent with those observed in the MTT assay. With
egard to apoptosis, a slight but significant increase of the
ub-G0/G1 fraction was only observed in the 5637 cancer
cell line. The RAD001 related reduction of mTOR ob-
served on 5637 cell was associated with a slight incr-
ease of upstream phospho-Akt. Therefore, inhibiting
mTORC1 release, the feedback inhibition mediated by
Fig. 6. Effect of 2M RAD001 on the expression of Akt, phospho-Akt, m
bars] and 5637 [grey bars]). Representative immunoblots are presented ab
SD. **p  0.01 versus untreated controls.the S6K-IRS1-PI3K loop that can lead to a paradoxical aincrease in Akt activity. Increased phosphorylated Akt
has been detected in tumor biopsies from patients treated
with rapalogs (mTOR inhibitors) [28].
Mansure et al. (2009) [27] found that RAD001 potently
inhibits proliferation in some of several cell lines (UM-
UC-3, UM-UC-5, UM-UC-6, UM-UC-9, and UM-UC-14)
with different stages of bladder tumorigenesis in vitro and
also significantly inhibits human bladder KU-7 tumor xeno-
grafts growing in nude mice, though no concomitant apo-
ptotic tumor cells were observed. These results revealed a
cytostatic effect with no significant change in the sub-G1
fraction and no cell loss in MTT assays.
Chiong et al. (2009) [29] also investigated the effect
AD001 had on human bladder-cancer cells (UM-UC3,
M-UC13) in vitro and in vivo. They observed heteroge-
eity in terms of in vitro responses to RAD001. The effect
f RAD001 was augmented by retreatment of the cells after
days. After retreatment, only sensitive cell lines showed
1 phase arrest, with no evidence of apoptosis. However,
AD001 did significantly inhibit the growth of tumor cells
hat were subcutaneously implanted in mice. Both authors
ound that the anti-tumor activity of RAD001 is related to
d phospho-mTOR in bladder cell lines (T24 [white bars], HT1376 [black
corresponding graphs. Data shown and bars represent the mean values TOR an
ove thengiogenesis inhibition. This was evidenced by the decrease
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10 C. Vasconcelos-Nóbrega et al. / Urologic Oncology: Seminars and Original Investigations xx (2011) xxxin VEGF production in vitro, and a significant reduction in
microvessels.
Curiously, in a similar direction, we previously observed
that 5637 cells, our most sensitive cell line, expressed nearly
4 times more VEGF-A than any other bladder cell lines
studied [22]. Therefore, angiogenesis inhibition may be the
redominant mechanism effect of sirolimus and its ana-
ogues [25,30].
It is important to underline that changes in tumor volume
nd angiogenesis observed in xenografts (nude mice) in-
uced by RAD001 cannot be compared with the develop-
ent of chemically induced bladder cancer in immune-
ompetent mice. More studies including the evaluation of
rotein synthesis inhibition through the S6K and 4E-BP1
athways, in order to clarify RAD001’s role in modulating
he carcinogenesis process, are required using this murine
odel. In our opinion and according to our results, it is
mportant to evaluate the effect of RAD001 prior to tumors
eing established, during the existence of pre-neoplastic
esions, which means before 12 weeks of BBN exposition.
In summary, RAD001 does not seem to have a signif-
cant effect on chemically induced murine bladder tumor-
genesis. The treatment was well tolerated. The effect of
AD001 on proliferation and apoptosis across different
ladder cancer cell lines is heterogeneous. Current
nowledge suggests the possibility of rapalogs integra-
ion in bladder cancer treatment protocol. However,
AD001 needs more clarification regarding the mecha-
ism of mTOR regulation and its role in the treatment of
ladder cancer.
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